Granules India Limited has announced that its wholly owned subsidiary, Granules Life Sciences Private Limited (GLS), has successfully completed a recent inspection by the United States Food and Drug Administration (US FDA) at its manufacturing facility in Shamirpet, Telangana. The inspection concluded with a classification of Voluntary Action Indicated (VAI), and the Establishment Inspection Report has been issued with no further regulatory action recommended.
The inspection, conducted between December 15 and 19, 2025, included a review of current Good Manufacturing Practices (cGMP) as well as a pre-approval inspection of the facility’s oral solid dosage manufacturing operations. The closure of the inspection without enforcement action reflects adherence to regulatory expectations and operational standards.
The VAI classification indicates that while certain observations may have been noted during the inspection, they do not warrant official action by the regulatory authority. This outcome reinforces the company’s ongoing efforts to maintain compliance while continuously improving quality systems and processes.
The development strengthens Granules India’s manufacturing network by enabling greater flexibility through multi-site production capabilities for approved products. This is expected to support supply chain resilience and enhance the company’s ability to meet growing demand across global markets.
Granules India operates as a vertically integrated pharmaceutical company, with capabilities spanning the entire value chain, including active pharmaceutical ingredients, intermediates, finished dosages, and specialized contract development and manufacturing services. The company serves a broad customer base across regulated and semi-regulated markets, with a presence in more than 80 countries.
With multiple manufacturing facilities across India, the United States, and Europe, the company maintains regulatory approvals from leading global authorities. Its operations are guided by a strong focus on quality, compliance, and customer service. The latest inspection outcome highlights the importance of sustained quality practices in the pharmaceutical industry, where regulatory compliance remains critical to ensuring patient safety and product reliability.
Granules India continues to emphasize continuous improvement as a core principle, investing in systems, infrastructure, and processes that support long-term operational excellence. The company remains committed to upholding high standards across all its facilities while expanding its global footprint and product portfolio.
